default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

Aprogen’s rheumatoid arthritis biosimilar wins sales approval in Japan

Lee Han-soo  기사승인 2017.09.27  17:45:00

공유
default_news_ad2

Aprogen Pharmaceuticals said Wednesday that the company’s NI-071 (Original: Remicade), a biosimilar that treats autoimmune diseases, has won a sales approval from Japan’s Ministry of Health, Labour and Welfare.

Two Japanese companies, Nichi-Iko Pharmaceutical and Yakuhan Pharmaceutical, which have partnered with Aprogen 에이프로젠, will be selling the treatment.

“Aprogen has become the third company in Korea to receive biosimilar sales approval in advanced markets following Celltrion 셀트리온 and Samsung Bioepis 삼성바이오에피스,” a company official said. “Although we started later than the two companies, we will increase market share based on competitive price.”

Japan’s Remicade market is known to be worth 1 trillion won ($876.4 million).

The company also plans to proceed and complete phase 3 clinical trials in the U.S. and apply for sales approval in America next year.

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch